Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP262 in Chronic Spontaneous Urticaria
2023-504799-94-00Phase 2Completed
- Sponsor
- Escient Pharmaceuticals
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing EP262 with Placebo (2 arms). Primary endpoint: Change in itch intensity and number of hives. Started Dec 2023; status: completed.
02
Drugs
EP262
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2023-504799-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504799-94-00.